Understanding SLC39A9: Potential Drug Target and Biomarker (G55334)

Target Name: SLC39A9

NCBI ID: G55334

SLC39A9

Understanding SLC39A9: Potential Drug Target and Biomarker

SLC39A9 (FLJ11274) is a protein that is expressed in various tissues throughout the body. It is a member of the sodium-dependent chloride channel (Na+/Cl- channel), which is a common channel found in many different cell types. SLC39A9 is also known as FLJ11274 because one of its human genes is located on chromosome 11 at position 274.

SLC39A9 is involved in many different cellular processes in the body, including the regulation of ion channels and the transport of molecules across cell membranes. It is also involved in the development and maintenance of tissues, such as the brain and heart.

SLC39A9 has been shown to be a potential drug target in the treatment of various diseases. For example, SLC39A9 has been shown to be involved in the development of epilepsy, and studies have suggested that inhibiting SLC39A9 function may be a useful treatment for this disease. Additionally, SLC39A9 has been shown to be involved in the development of cancer, and inhibiting its function may be a potential cancer treatment.

SLC39A9 is also a potential biomarker for certain diseases. For example, SLC39A9 has been shown to be elevated in the blood of people with Alzheimer's disease, a degenerative brain disorder. Additionally, SLC39A9 has been shown to be elevated in the urine of people with certain forms of cancer, which may indicate the presence of these diseases.

Despite these promising findings, more research is needed to fully understand the role of SLC39A9 in the body and its potential as a drug target or biomarker.

In conclusion, SLC39A9 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of ion channels and the transport of molecules across cell membranes. It has also been shown to be involved in the development and maintenance of tissues and in the development of certain diseases. Further research is needed to fully understand the role of SLC39A9 in the body and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 39 Member 9

Functions: Transports zinc ions across cell and organelle membranes into the cytoplasm and regulates intracellular zinc homeostasis (PubMed:25014355, PubMed:19420709, PubMed:28219737). Participates in the zinc ions efflux out of the secretory compartments (PubMed:19420709). Regulates intracellular zinc level, resulting in the enhancement of AKT1 and MAPK3/MAPK1 (Erk1/2) phosphorylation in response to the BCR activation (PubMed:23505453). Also functions as membrane androgen receptor that mediates, through a G protein, the non-classical androgen signaling pathway, characterized by the activation of MAPK3/MAPK1 (Erk1/2) and transcription factors CREB1 or ATF1 (By similarity). This pathway contributes to CLDN1 and CLDN5 expression and tight junction formation between adjacent Sertoli cells (By similarity). Mediates androgen-induced vascular endothelial cell proliferation through activation of an inhibitory G protein leading to the AKT1 and MAPK3/MAPK1 (Erk1/2) activation which in turn modulate inhibition (phosphorylation) of GSK3B and CCND1 transcription (PubMed:34555425). Moreover, has dual functions as membrane-bound androgen receptor and as an androgen-dependent zinc transporter both of which are mediated through an inhibitory G protein (Gi) that mediates both MAP kinase and zinc signaling leading to the androgen-dependent apoptotic process (PubMed:25014355, PubMed:28219737)

The "SLC39A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC39A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets